image:Compared with a control (left), treatment with SLR14 (right) reduces the signs of inflammation and pneumonia in the lungs of SARS-CoV-2infected mice. view more
Credit: 2021 Mao et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20211818
Researchers at Yale School of Medicine have discovered that an RNA molecule that stimulates the bodys early antiviral defense system can protect mice from a range of emerging SARS-CoV-2 variants. The study, published today in the Journal of Experimental Medicine (JEM), could lead to new treatments for COVID-19 in immunocompromised patients, as well as providing an inexpensive therapeutic option for developing countries that currently lack access to vaccines.
Though approved vaccines against SARS-CoV-2 are highly effective at preventing severe disease and death during the ongoing COVID-19 pandemic, vaccine availability is extremely limited in many low-income countries, and new, vaccine-resistant strains of the virus could emerge in the future. Moreover, the vaccines effectiveness is already reduced in immunocompromised individuals unable to form sufficient numbers of antibodies or T cells that specifically target the viral spike protein. These individuals are susceptible to chronic, long-term SARS-CoV-2 infections.
This is why, in addition to the use of vaccines in preventing COVID-19, efforts are required to develop efficacious therapeutics against SARS-CoV-2, says Akiko Iwasaki, a professor at Yale School of Medicine.
The bodys first line of defense against SARS-CoV-2before the involvement of antibodies and T cellsis thought to depend on receptor molecules such as RIG-I that recognize the viruss genetic material and induce the production of signaling proteins known as type I interferons. These interferons, in turn, promote the production of proteins that can inhibit viral replication and stimulate the recruitment of immune cells to fight the infection.
Multiple studies have suggested that early and robust production of interferons protects against COVID-19, whereas delayed production is associated with severe disease. A clinical trial has shown that treating COVID-19 patients with purified interferon protein early during disease can reduce mortality, but manufacturing interferons is extremely expensive.
In the new JEM study, Iwasaki and colleagues suggest a cheaper alternative: treating patients with short RNA molecules that mimic SARS-CoV-2s genetic material and activate the RIG-I receptor to stimulate production of type I interferons by the bodys own cells.
The researchers tested their approach in mice susceptible to SARS-CoV-2 infection. A single dose of an RNA molecule named SLR14 was sufficient to protect the mice from severe disease and death, particularly if the treatment was provided shortly before or soon after exposure to the virus. When administered shortly after viral infection, SLR14 was more effective than treating mice with purified interferon protein, the researchers determined.
Crucially, SLR14 protected mice from all emerging SARS-CoV-2 variants, including the delta variant responsible for the recent surge in US COVID-19 cases.
Finally, Iwasaki and colleagues tested SLR14 in immunocompromised Rag-/- mice chronically infected with SARS-CoV-2. The RNA molecule was able to completely clear the virus from these animals, even though they lack both T cells and antibody-producing B cells.
Iwasaki and colleagues point out that RNA molecules like SLR14 are relatively cheap and easy to manufacture. SLR14 therefore holds great promise as a new class of RNA therapeutics that can be applied as antivirals against SARS-CoV-2, Iwasaki says. Moreover, because this RNA-based therapeutic approach is simple and versatile, our study will facilitate pandemic preparedness and response against future respiratory pathogens sensitive to type I interferons.
Mao et al. 2021. J. Exp. Med. https://rupress.org/jem/article-lookup/doi/10.1084/jem.20211818?PR
# # #
About Journal of Experimental Medicine
Journal of Experimental Medicine (JEM)publishes peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Established in 1896, JEMis published by Rockefeller University Press, a department of The Rockefeller University in New York. For more information, visit jem.org.
Visit our Newsroomand sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.
Follow JEMon Twitter at @JExpMedand @RockUPress.
Journal of Experimental Medicine
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
T. Mao reported a patent to US20210102209A1pending. C.B. Wilen reported a patent pending related to thiswork entitled "Compounds and Compositions for Treating,Ameliorating, and/or Preventing SARS-CoV-2 Infection and/orComplications Thereof"; and reported, "This work was supportedby K08 AI128043, Burroughs Wellcome Fund, LudwigFamily Foundation, and Mathers Charitable Foundation." N.D.Grubaugh reported personal fees from Tempus Labs and theNational Basketball Association, and grants from the CDC andFast Grants during the conduct of the study. A.M. Pyle reported apatent to SLR14 patent pending. A.M. Pyle and A. Iwasaki are cofoundersof RIGImmune, a company that is developing agonistsfor the RIG-I receptor, including SLR compounds. A. Iwasakireported a patent number 10947543 issued (Yale UniversitySchool ofMedicine), served as a consultant for Spring Discovery,Boehringer Ingelheim, and Adaptive Biotechnologies, and is amember of the scientific advisory board of 4BIO Capital. Noother disclosures were reported.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Go here to see the original:
- University of Michigan Stem Cell Research | Frequently ... - November 30th, 2021
- Postdoctoral Research Associate in Centre for Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 273388 - Times Higher Education... - November 30th, 2021
- Stem cell therapy potentially could treat Type 1 diabetes by helping patients produce insulin - USA TODAY - November 30th, 2021
- UCLA Broad Stem Cell Research Center receives $5 million ... - November 30th, 2021
- ReproCELL Incorporated : Everything you need to know about the REPROCELL iPSC Biobank - marketscreener.com - November 30th, 2021
- Cell therapy biotech Quell adds $156M for alternative to organ transplant meds - MedCity News - November 30th, 2021
- New nanochip reprograms cells in the body to perform different functions - New Atlas - November 30th, 2021
- Inside the Innovative Lab Growing Mammal Tissue Using Plants as Scaffolds - Smithsonian - November 30th, 2021
- BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn in ALS at the 4th Annual ALS ONE Research... - November 30th, 2021
- 'Sleeping' cancer cells explain why childhood leukaemia returns after years of treatment - The Institute of Cancer Research, London - The Institute of... - November 30th, 2021
- 10 rare cancers: Symptoms, treatment, and more - Medical News Today - November 30th, 2021
- Heart repair and regeneration after a heart attack a review - The Mix - November 30th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - StreetInsider.com - November 27th, 2021
- How the CGT Catapult plans to bridge the gap between scientific research and commercialisation - The Scotsman - November 27th, 2021
- Global $512M+ Exosome Diagnostics & Therapeutics Market, 2026 | Featuring Profiles of Codiak Biosciences, Evox Therapeutics, Exosome Diagnostics,... - November 27th, 2021
- Discovering a new gene in monkeys that could help to develop new antivirals - News-Medical.net - November 27th, 2021
- 2nd Person May Be Naturally 'Cured' of HIV: What Science Is Learning - Healthline - November 27th, 2021
- Research Roundup: Masking Cuts COVID-19 Risk in Half and More Research News - BioSpace - November 27th, 2021
- Stem Cell Research Facts - November 24th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - marketscreener.com - November 24th, 2021
- Research Developments in the Treatment of Advanced Kidney Cancer - Warwick Beacon - November 24th, 2021
- Covid vaccine: Stem cell transplant patients who must be completely re-vaccinated struggling to book jabs - iNews - November 24th, 2021
- Amity University partners with top US varsities for academics and research - Telegraph India - November 24th, 2021
- AML relapse: Definition, statistics, and treatment options - Medical News Today - November 24th, 2021
- Its too late for me but please help others with cancer - Melton Times - November 22nd, 2021
- Research Developments in the Treatment of Advanced Kidney Cancer - The Apopka Voice - November 22nd, 2021
- How The Overlap Between Artificial Intelligence And Stem Cell Research Is Producing Exciting Results - Forbes - November 22nd, 2021
- California Proposition 14, Stem Cell Research Institute ... - November 22nd, 2021
- Theres Something Neurological Going On, COVID Could Cause Depression And Anxiety, Researchers Say - CBS Baltimore - November 22nd, 2021
- Exosome Diagnostics and Therapeutics: Global Markets - Yahoo Finance - November 22nd, 2021
- Flying cars and floating cities these 8 radical designs predict our imminent future - Boston News, Weather, Sports | WHDH 7News - November 22nd, 2021
- Researchers discover new type of cell that may help regulate heart rate - News-Medical.net - November 22nd, 2021
- The Promise of Stem Cells to Help Children with Autism - Entrepreneur - November 21st, 2021
- Stem cell transplants without chemo and radiation first? - Futurity: Research News - November 16th, 2021
- Unregulated Stem Cell Clinics Endanger Patients And Limit Research - Forbes - November 16th, 2021
- Regenerative Medicine Market Size Worth $ ~41.45 billion by 2031 - Market Size, Share, Forecasts and Trends Analysis Report with COVID-19 Impact by... - November 16th, 2021
- Stem Cell Therapy Reduces Need for Nearly 10% of Hip Replacements - Yale School of Medicine - November 16th, 2021
- Overlooked DNA may be what separates humans from other primates study - The Jerusalem Post - November 16th, 2021
- In-depth Research on Cancer Stem Cell Market Forecast Estimation & Approach 2021-2026 | Thermo Fisher Scientific, AbbVie, Merck KGaA, Bionomics,... - November 16th, 2021
- NK Cell Therapy and Stem Cell Therapy Market Cumulative Impact for COVID-19 Recovery Research Report 2021 | Takeda Pharmaceutical, JCR Pharmaceutical,... - November 16th, 2021
- Stem Cell Therapy Market Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2027|Osiris Therapeutics, NuVasive, Chiesi... - November 16th, 2021
- Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT - Yahoo Finance - November 16th, 2021
- Research Antibodies Market Size Is Projected to Reach $6.35 Billion by 2028 | CAGR: 6.5% : Polaris Market Research - PRNewswire - November 16th, 2021
- Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update - Tyler Morning Telegraph - November 16th, 2021
- $2.26 million in grants will support biomedic - EurekAlert - November 16th, 2021
- What science knows about stem cells and what it predicts in the future | CoFounder - CoFounder Magazine - November 11th, 2021
- Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral... - November 11th, 2021
- Stem Cell Characterization and Analysis Tool Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: Osiris Therapeutics,... - November 11th, 2021
- Global Stem Cell Umbilical Cord Blood (UCB) Market Insightful Research Report: Business Growth, Development Factors, Current and Future Trends and... - November 11th, 2021
- Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates - The Bakersfield Californian - November 11th, 2021
- 2021 Boston Investment Conference Marks Decade of Helping Fund Critical Research at Boston Childrens Hospital - Yahoo Finance - November 11th, 2021
- Critical Link Discovered Between Dietary Fat and the Spread of Cancer - SciTechDaily - November 11th, 2021
- Opinion | How Covid Raised the Stakes of the War Between Faith and Science - The New York Times - November 11th, 2021
- EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and... - November 5th, 2021
- Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update - Yahoo... - November 5th, 2021
- City of Hope Doctors Present New Research on Cancer Immunotherapies - Business Wire - November 5th, 2021
- Mini-brain model of frontotemporal dementia demonstrates the stages of dysfunction that lead to cell death - National Institute on Aging - November 5th, 2021
- Intestinal Organoids and Their Role in Tissue Engineering - Technology Networks - November 5th, 2021
- Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights - Business Wire - November 5th, 2021
- Researchers generate and characterize the hepatic organoid culture system - News-Medical.net - November 3rd, 2021
- A major research project to advance regenerative therapy for epidermolysis bullosa (EB) using transgenic stem cells - PR Web - November 3rd, 2021
- Canada Biobanks Markets, Analysis & Forecasts, 2016-2020 & 2021-2026 - Increased Research and Technological Advancement in Genomic Studies -... - November 3rd, 2021
- Study paves the way for a better understanding of muscle injury - News-Medical.Net - November 3rd, 2021
- Lab-Growing Everything Might Be The Only Way To Attain A Sustainable World - Intelligent Living - November 3rd, 2021
- What is Stem Cell Research? | The Benefits of Stem Cell ... - October 26th, 2021
- New Treatments and Tips for Dealing With Blood Cancer - Curetoday.com - October 26th, 2021
- NK Cell Therapy and Stem Cell Therapy Market Cumulative Impact for COVID-19 Recovery Research Report 2021 | Chiesi Pharmaceuticals, Takeda... - October 25th, 2021
- Skroot Laboratory, Inc. Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery - KOLO - October 23rd, 2021
- New GBM research pipeline and being glad - Brain Tumour Research - October 23rd, 2021
- Excellent Growth of Cell Separation Technology Market by Trends, Dynamic Innovation and Key Players GE, BD, Terumo, Merck, Thermo Fisher | Forecast... - October 23rd, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - UB Now: News and views for UB faculty and staff -... - October 21st, 2021
- What Makes Us Human? The Answer May Be Found in Overlooked Junk DNA - SciTechDaily - October 21st, 2021
- Stem Cell Therapy Market SWOT Analysis, Key Indicators, Forecast 2027 | Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), Osiris... - October 21st, 2021
- Stem Cell Therapy Market: Shaping Tomorrow with Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), Osiris Therapeutics Puck77 -... - October 21st, 2021
- Liu receives Catalyst Award from the National Institutes of Health agency - Harvard School of Engineering and Applied Sciences - October 21st, 2021
- Stem Cell Therapy Market 2021 Financial Highlights Analysis with Top Key Players: Anterogen Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea),... - October 21st, 2021
- Stem Cell Therapy Market 2025 Size, Key Companies, Trends, Growth And Regional Forecasts Research | Anterogen Co., Ltd. (South Korea), MEDIPOST Co.,... - October 21st, 2021
- Scientists use human-derived brain cells to develop more realistic 'disease-in-a-dish' models of Alzheimer's - National Institute on Aging - October 21st, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 17th, 2021
- Research Roundup: T-Cell Immune Response to COVID-19 Vaccines and More - BioSpace - October 17th, 2021